Infliximab leaflet

Infliximab Therapeutic Drug Monitoring

Serum Infliximab and Total Anti-Infliximab Antibodies

 

Infliximab (Remicade®), is a chemeric human-mouse monoclonal antibody directed against tumour necrosis factor-alpha (TNF ), approved for use in the treatment of various chronic inflammatory diseases including rheumatoid arthritis, severe crohn's disease and ankylosing spondylitis. We measure serum infliximab using an in-house ELISA method.

Download Information Leaflet here...

 

 

Test:

 Infliximab Therapeutic Drug Monitoring

Laboratory

Clinical Biochemistry

Specimen Type:

0.5 mL Serum

Storage:

-20°C prior to dispatch

Posting Details:

ambient temperature, first class post

Posting Address:

Department of Clinical Biochemistry, City Hospital, Dudley Road, Birmingham B18 7QH

Clinical Use:

Effective use of Infliximab in clinical practice. To assess reasons for a lack of clinical response.

Pricing:

Serum Infliximab: 25
Anti-Infliximab antibodies: 35

Turnaround:

Serum Infliximab Assay- within  3 working days

Anti-Infliximab Antibodies Assay - within 7 working days

External QA Scheme:

Not Applicable

CPA Accredited Lab/Test:

Yes, CPA Full Accreditation

Website:

www.cityassays.org.uk

Clinical Lead for this assay:

Dr Nicola Barlow

Tel : 0121 507 3517
Email: nicola.barlow1@nhs.net

 

 

 

 

 

  SWBH NHS Trust 2017